IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
IGC Pharma (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, announced that its Principal Scientist, Dr. Jagadeesh Rao, has received the Best Researcher Award at the 11th Annual World Neuroscientist Awards. The recognition comes from an international panel of experts, highlighting his 15+ years of scientific leadership in neuroscience research.
Dr. Rao's work has been crucial in advancing IGC-AD1, the company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients. His selection came from a competitive pool of over 360 nominations across 125 countries.
IGC Pharma (NYSE American:IGC), un'azienda biofarmaceutica in fase clinica specializzata nella malattia di Alzheimer, ha annunciato che il suo Scienziato Principale, Dr. Jagadeesh Rao, ha ricevuto il Premio al Miglior Ricercatore agli 11° Annuali World Neuroscientist Awards. Il riconoscimento, conferito da una giuria internazionale di esperti, sottolinea la sua leadership scientifica di oltre 15 anni nella ricerca neuroscientifica.
Il lavoro del Dr. Rao è stato fondamentale per il progresso di IGC-AD1, il farmaco sperimentale dell'azienda attualmente in fase 2 di sperimentazione clinica per il trattamento dell'agitazione nei pazienti con Alzheimer. La sua selezione è avvenuta tra una competizione con oltre 360 candidature provenienti da 125 paesi.
IGC Pharma (NYSE American:IGC), una compañía biofarmacéutica en etapa clínica enfocada en la enfermedad de Alzheimer, anunció que su Científico Principal, Dr. Jagadeesh Rao, ha recibido el Premio al Mejor Investigador en la 11ª Edición Anual de los World Neuroscientist Awards. El reconocimiento proviene de un panel internacional de expertos, destacando su más de 15 años de liderazgo científico en investigación en neurociencia.
El trabajo del Dr. Rao ha sido clave para el avance de IGC-AD1, el fármaco en investigación de la compañía que actualmente se encuentra en ensayos de Fase 2 para tratar la agitación en pacientes con Alzheimer. Su selección surgió de una competencia con más de 360 nominaciones de 125 países.
IGC Pharma (NYSE American:IGC)는 알츠하이머병에 집중하는 임상 단계 바이오제약 회사로, 수석 과학자인 Dr. Jagadeesh Rao가 제11회 연례 세계 신경과학자 시상식에서 최우수 연구자상을 수상했다고 발표했습니다. 이 상은 국제 전문가 패널로부터 수여되었으며, 그의 15년 이상의 신경과학 연구 리더십을 인정받은 것입니다.
Dr. Rao의 연구는 현재 알츠하이머 환자의 불안을 치료하기 위해 2상 임상시험 중인 회사의 실험 약물 IGC-AD1 개발에 중요한 역할을 했습니다. 그의 선정은 125개국에서 온 360건 이상의 후보 중에서 이루어졌습니다.
IGC Pharma (NYSE American:IGC), une société biopharmaceutique en phase clinique spécialisée dans la maladie d'Alzheimer, a annoncé que son scientifique principal, Dr Jagadeesh Rao, a reçu le prix du meilleur chercheur lors de la 11e édition annuelle des World Neuroscientist Awards. Cette distinction, décernée par un jury international d'experts, souligne ses plus de 15 ans de leadership scientifique en recherche en neurosciences.
Le travail du Dr Rao a été déterminant dans l'avancement de IGC-AD1, le médicament expérimental de la société actuellement en phase 2 d'essais cliniques pour traiter l'agitation chez les patients atteints d'Alzheimer. Sa sélection est issue d'une compétition regroupant plus de 360 candidatures provenant de 125 pays.
IGC Pharma (NYSE American:IGC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Alzheimer, gab bekannt, dass sein leitender Wissenschaftler, Dr. Jagadeesh Rao, mit dem Best Researcher Award bei den 11. jährlichen World Neuroscientist Awards ausgezeichnet wurde. Die Anerkennung stammt von einem internationalen Expertengremium und hebt seine über 15 Jahre wissenschaftliche Führungsrolle in der Neurowissenschaft hervor.
Dr. Raos Arbeit war entscheidend für die Weiterentwicklung von IGC-AD1, dem experimentellen Medikament des Unternehmens, das sich derzeit in Phase-2-Studien zur Behandlung von Unruhe bei Alzheimer-Patienten befindet. Seine Auswahl erfolgte aus einem Wettbewerb mit über 360 Nominierungen aus 125 Ländern.
- None.
- None.
POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards.
Dr. Rao was selected through a rigorous evaluation by an international panel of academic and industry experts in clinical drug development and neuroscience research. The award recognizes his extensive contributions across neuroscience, psychiatry, neuropharmacology, molecular biology, and biochemistry, underscoring more than 15 years of scientific leadership and innovation in the field.
"This global recognition of Dr. Rao's accomplishments reinforces IGC Pharma's commitment to scientific excellence and its leadership in advancing novel therapeutics for Alzheimer's disease," said Ram Mukunda, CEO of IGC Pharma. "Dr. Rao's expertise in neuroscience and regulatory science is instrumental to our drug development programs, and this award highlights the caliber of talent driving our mission to deliver effective treatments for patients."
Dr. Rao's recent work includes publications on neurobiological alterations in agitation in Alzheimer's disease, as well as studies on epigenetic changes in the frontal cortex of Alzheimer's and bipolar disorder patients. His contributions have been central to the advancement of IGC-AD1, the Company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients.
The World Neuroscientist Awards received over 360 nominations from researchers across 125 countries, making Dr. Rao's selection a noteworthy acknowledgment of the global relevance and quality of his work.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information
Rosalyn Christian/Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is Dr. Jagadeesh Rao and what award did he receive from IGC Pharma in 2025?
What is IGC-AD1 and what stage of development is it in?
What is IGC Pharma's main focus in drug development?
What are Dr. Rao's key research areas at IGC Pharma?
